IP Library Granted Patent US 12,410,422
Granted Patent B2
US 12,410,422 · App. 17/130,114 · Granted Sep 9, 2025

Methods for purification of messenger RNA

Inventors: Frank DeRosa (Lexington, MA); Michael Heartlein (Lexington, MA); Jonathan Abysalh (Lexington, MA); Daniel Crawford (Lexington, MA); Anusha Dias (Lexington, MA); Shrirang Karve (Lexington, MA)
Assignee: TRANSLATE BIO, INC.
C12N15/1003C07H21/04C12N15/1006C12N15/1017C12N15/1065C12N2310/10C12Y201/03003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,422
App. No.
17/130,114
Granted
Sep 9, 2025
Kind
B2
Abstract

The present invention relates, in part, to methods for large-scale purification of mRNA. The method includes, at least, a step of centrifuging an mRNA suspension in a centrifuge comprising a porous substrate at a speed sufficient to remove process contaminants and to precipitate purified mRNA composition onto the porous substrate.

Claims (16)

1. A composition comprising at least 10 grams of dried purified mRNA, wherein said mRNA is obtained by a method for large-scale purification of mRNA, comprising the steps of:

providing a suspension comprising precipitated mRNA manufactured by in vitro synthesis; and

centrifuging the suspension at a speed of about 1000 to 5000 RPM in a centrifuge comprising a porous substrate such that the precipitated mRNA is captured on the porous substrate, and contaminants are removed from the precipitated mRNA to provide captured purified mRNA;

washing the captured purified mRNA composition with a solvent; and

drying the captured purified mRNA, thereby obtaining dried purified mRNA in the form of a solid,

wherein the purified mRNA yield is at least about 80% and is substantially free of prematurely aborted RNA sequences, DNA templates, and one or more enzyme reagents used in in vitro synthesis;

wherein the dried purified mRNA is collected and stored as a solid at a temperature of or below about 0° C. for a period of at least about one week to about two years; and

wherein the dried purified mRNA has substantially the same integrity as prior to storage.

2. The composition of claim 1 , wherein said suspension comprising precipitated mRNA manufactured by in vitro synthesis comprises at least about 25 grams, 50 grams, 100 grams, or 1 kilogram of precipitated mRNA.

3. The composition of claim 1 , wherein the enzyme reagents used in in vitro synthesis comprise T7 RNA polymerase, SP6 RNA polymerase, DNAse I, pyrophosphatase, and/or RNAse inhibitor.

4. The composition of claim 1 , wherein the mRNA encodes cystic fibrosis transmembrane receptor (CFTR).

5. The composition of claim 1 , wherein the mRNA encodes ornithine transcarbamylase (OTC).

6. The composition of claim 1 , wherein the washing of the captured purified mRNA occurs via centrifugation.

7. The composition of claim 1 , wherein the drying of the captured purified mRNA occurs via centrifugation.

8. The composition of claim 1 , wherein said dried purified mRNA is obtained by a method further comprising collecting the dried purified mRNA from the porous substrate while the centrifuge is centrifuging.

9. The composition of claim 1 , wherein the dried purified mRNA can be sectioned into manageable pieces.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2020
From: TRANSLATE BIO MA, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 054725/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2020
From: DEROSA, FRANK; HEARTLEIN, MICHAEL; ABYSALH, JONATHAN; CRAWFORD, DANIEL; DIAS, ANUSHA; KARVE, SHRIRANG
To: TRANSLATE BIO MA, INC.
Reel/Frame 054725/0588 →
Continuity (3)
Division 15907086 · Feb 27, 2018
Provisional Application 62463981 · Feb 27, 2017
Related Publication 20210180041A1 · Jun 17, 2021
References Cited (59)
US 5571669A · Lu · 1996 [cited by applicant]
US 5874268A · Meyer · 1999 [cited by examiner]
US 6180778B1 · Bastian · 2001 [cited by applicant]
US 9308281B2 · Guild · 2016 [cited by applicant]
US 9850269B2 · DeRosa · 2017 [cited by examiner]
US 10155785B2 · Derosa · 2018 [cited by applicant]
US 10975369B2 · DeRosa · 2021 [cited by examiner]
US 20020042080A1 · Woods · 2002 [cited by applicant]
US 20020044919A1 · Yu · 2002 [cited by applicant]
US 20020151067A1 · Garoff · 2002 [cited by applicant]
US 20030083272A1 · Wiederholt · 2003 [cited by applicant]
US 20030083274A1 · Wright · 2003 [cited by applicant]
US 20040009541A1 · Singh · 2004 [cited by applicant]
US 20040039210A1 · Cheng · 2004 [cited by applicant]
US 20050048045A1 · Shetty · 2005 [cited by applicant]
US 20050181460A1 · Ohno · 2005 [cited by applicant]
US 20060051834A1 · Strey · 2006 [cited by applicant]
US 20070053879A1 · Gregory · 2007 [cited by examiner]
US 20070066552A1 · Clarke · 2007 [cited by applicant]
US 20080248559A1 · Inomata · 2008 [cited by applicant]
US 20100326827A1 · Lin · 2010 [cited by applicant]
US 20120142756A1 · Guild · 2012 [cited by applicant]
US 20130156849A1 · de Fougerolles · 2013 [cited by examiner]
US 20130259924A1 · Bancel · 2013 [cited by examiner]
US 20140273058A1 · Menon · 2014 [cited by applicant]
US 20140343129A1 · De Fougerolles · 2014 [cited by applicant]
US 20150119566A1 · Li · 2015 [cited by applicant]
US 20150376220A1 · Derosa · 2015 [cited by applicant]
US 20160038612A1 · Hoge · 2016 [cited by applicant]
US 20170056526A1 · Dohmen · 2017 [cited by applicant]
US 20180002393A1 · Bancel · 2018 [cited by applicant]
US 20180085391A1 · Bouchon · 2018 [cited by applicant]
US 20180201967A1 · Eber · 2018 [cited by applicant]
US 20180256750A1 · Butora · 2018 [cited by applicant]
US 20190054112A1 · Gregoire · 2019 [cited by applicant]
WO WO9527721A1 · 1995 [cited by examiner]
WO WO2014144767A1 · 2014 [cited by applicant]
WO WO2015164773A1 · 2015 [cited by applicant]
WO WO2016193206A1 · 2016 [cited by applicant]
Chen et al., An overview of liposome lyophilization and its future potential. J. of Controlled Release 142:299-311 (Year: 2010). [cited by examiner]
Crommelin et al., Addressing the cold reality of mRNA vaccine stability. J. of Pharm. Sciences 110:997-1001 (Year: 2021). [cited by examiner]
Damen et al. J. of Virological Methods 72: 175-184 (Year: 1998). [cited by examiner]
Jones et al., Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques 43:675-681 (Year: 2007). [cited by examiner]
Kasper et al., Euro. J. of Pharmaceutics and Biopharmaceutics85:162-169 (Year: 2013). [cited by examiner]
Krieg et al., Functional messenger RNA produced by SP6 in vitro transcription of cloned cDNA. Nucleic Acids Research12(18) : 7057 (Year: 1984). [cited by examiner]
Merivaara et al., J. of Controlled Release 336:480-498 (Year: 2021). [cited by examiner]
Pearson et al., Simple and Rapid RNA extraction from freeze-dried tissue of brown algae and saegrasses. Euro. J. Phycol. 41:97-104 (Year: 2006). [cited by examiner]
Pollard et al., Challenges and advances towards the rational design of mRNA vaccines. Trends in Molecular Medicine 19(12) : 705 (Year: 2013). [cited by examiner]
Wang et al., Molecular Genetics and Metabolism 105: 203-211 (Year: 2012). [cited by examiner]
Zimmer et al.,Molecular Medicine5:244-253 (Year: 1999). [cited by examiner]
Jones et al., Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques 43(5) : 675 (Year: 2007). [cited by examiner]
Kelly, B., Very Large scale monoclonal antibody purification : the case for conventional unit operations. Biotechnology Progress 23:995-1008 (Year: 2007). [cited by examiner]
Pascolo, S., Messenger RNA-based vaccines. Expert opinion on biological therapy 4(8) : 1285-1294 (Year: 2004). [cited by examiner]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/US2018/019978, mailed Aug. 30, 2018. [cited by applicant]
Kirikó et al., “Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector with Increased Translational; Capacity and Biological Stability”, Molecular Therapy, 2009. 16(11): 1833. [cited by applicant]
Moldow et al., “Purification of Bacterial Membrane Proteins”, J of Memb Biology, 1972, 10: 137. [cited by applicant]
Sahin et al., “mRNA-based Therapeutics—developing a new class of drugs”, Nature Reviews/Drug Discovery, 2014, 13: 759. [cited by applicant]
Karikó, K. et al., “Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA”, Nucleic Acids Research, GB, vol. 39, N… [cited by applicant]
Sahin, U. et al., “mRNA-based therapeutics—developing a new class of drugs”, Nature Reviews Drug Discovery, vol. 13, No. 10, Sep. 19, 2014, pp. 759-780. [cited by applicant]